Skip to main content

Table 3 Appropriateness of empiric therapy

From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

 

Ceftolozane/tazobactam

Piperacillin/tazobactam

Resistant to initial therapy (%)

7.8

20.2

Susceptible to initial therapy (%)

92.2

79.8

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us